Advances in the pharmacological management of early motor manifestations of Parkinson’s disease (PD)

The diagnosis of PD at the onset of motor symptoms is already late in terms of disease progression. An easy-to apply, reliable, sensitive diagnostic biomarker for predictive screening is currently outstanding. Nevertheless, the ability to delay progression and/or cure of the disease is currently the greatest unmet need. Chronic neurodegenerative processes arise from various distinct yet interconnected metabolic and pathological cascade sequences that work together. The translation of promising treatments concepts for beneficial disease modification has failed once they were tested in levodopa-naive patients. Microbiome alteration with short fatty acids or acetyl-DL-leucine supplementation, only enhance levodopa efficacy, But do not modify disease progression in a benefical way. Presently, there is also a lack of real innovation in terms of dopamine substitution.